These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 220936)

  • 21. [Effect and tolerance of the angiotensin-converting enzyme inhibitor captopril (Tensobon)].
    Rahn KH; Stumpe KO
    MMW Munch Med Wochenschr; 1984 Feb; 126 Suppl 1():S5-14. PubMed ID: 6323979
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of essential arterial hypertension of moderate severity with an orally active inhibitor of the angiotensin converting enzyme (Captopril)].
    Guerrera G; Melina D
    Minerva Cardioangiol; 1983 Mar; 31(3):101-6. PubMed ID: 6304570
    [No Abstract]   [Full Text] [Related]  

  • 23. Angiotensin converting enzyme inhibition: a new therapeutic modality.
    Gavras H; Charocopos F; Brunner H; Gavras I
    Bull N Y Acad Med; 1981 May; 57(4):304-10. PubMed ID: 6164426
    [No Abstract]   [Full Text] [Related]  

  • 24. [Inhibitors of angiotensin-converting enzyme in the treatment of arterial hypertension].
    Salvetti A; Pedrinelli R; Abdel-Haq B; Magagna A; Lucarini A; Graziadei L; Nuccorini A; Taddei S
    Cardiologia; 1984; 29(1-2):103-20. PubMed ID: 6085475
    [No Abstract]   [Full Text] [Related]  

  • 25. Modern concepts in the drug treatment of arterial hypertension.
    van Zwieten PA
    Int J Clin Pharmacol Ther Toxicol; 1980 Sep; 18(9):412-9. PubMed ID: 6108920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertension screening and treatment with angiotensin inhibitors. Saralasin and captopril.
    Zawada ET; Stinson J; Ramirez G
    Postgrad Med; 1980 Oct; 68(4):89-92, 94-5, 98. PubMed ID: 6999479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A new point of attack for the treatment of hypertension; captopril, an orally active inhibitor of the enzymatic conversion of angiotensin I into angiotensin II].
    Schalekamp MA; de Bruyn JH; Wenting GJ; Man in 't Veld AJ; Derkx FH
    Ned Tijdschr Geneeskd; 1980 Nov; 124(47):1996-2003. PubMed ID: 6255350
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of hypertension with angiotensin converting enzyme inhibitors.
    Johnston CI; McGrath BP; Matthews PG; Jackson B
    Clin Exp Pharmacol Physiol Suppl; 1982; 7():135-44. PubMed ID: 6183036
    [No Abstract]   [Full Text] [Related]  

  • 29. [Therapeutic strategy in arterial hypertension].
    Waeber B; Nussberger J; Brunner HR
    Schweiz Med Wochenschr; 1987 Feb; 117(7):227-38. PubMed ID: 2882599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-converting enzyme inhibitors: pathogenic and therapeutic implications for arterial hypertension.
    Waeber B; Brunner HR; Wauters JP; Gavras H
    Adv Nephrol Necker Hosp; 1981; 10():111-33. PubMed ID: 6267906
    [No Abstract]   [Full Text] [Related]  

  • 31. Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol.
    Sasaki J; Koga S; Kato K; Takii M; Sakai K; Kawasaki K; Kagimoto M; Doi Y; Takada K; Sakaue A
    Int J Clin Pharmacol Ther Toxicol; 1993 Feb; 31(2):83-8. PubMed ID: 8458681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of the hypertensive crisis by blocking the renin-angiotensin system (author's transl)].
    Wambach G; Kaufmann W
    MMW Munch Med Wochenschr; 1982 Jul; 124(27):638-40. PubMed ID: 6810156
    [No Abstract]   [Full Text] [Related]  

  • 33. Captopril and enalapril: angiotensin converting enzyme (ACE) inhibitors.
    Ferguson RK; Vlasses PH; Riley LJ
    Ration Drug Ther; 1984 Mar; 18(3):1-5. PubMed ID: 6093192
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical experience with a new antihypertensive drug (captopril SQ 14.225), an oral inhibitor of converting enzyme].
    Santucci A; Aguglia F; Ficara C
    Clin Ter; 1981 Apr; 97(1):43-58. PubMed ID: 6269793
    [No Abstract]   [Full Text] [Related]  

  • 35. Hemodynamic alterations associated with progression of renal allograft injury.
    Bochicchio T; Ron O; Sandoval G; Pérez-Grovas H; Bordes J; Herrera-Acosta J
    Transplant Proc; 1991 Apr; 23(2):1773-4. PubMed ID: 1828917
    [No Abstract]   [Full Text] [Related]  

  • 36. Captopril, an orally active angiotensin I converting enzyme inhibitor in the treatment of renovascular and essential hypertension.
    Holtzman E; Rosenthal T; Stern N; Knecht A; Yaron A
    Isr J Med Sci; 1982 May; 18(5):597-602. PubMed ID: 6284678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Converting enzyme inhibition to identify and treat renin-mediated or sodium-volume related forms of increased peripheral resistance in hypertension and in congestive heart failure.
    Cody RJ; Laragh JH; Atlas SA; Case DB
    J Hypertens Suppl; 1983 Oct; 1(1):77-84. PubMed ID: 6085835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current clinical use of converting enzyme inhibitors].
    Corvol P; Plouin PF; Castaigne A; Palsky E
    Rev Prat; 1982 Jan; 32(1):75-82. PubMed ID: 6275488
    [No Abstract]   [Full Text] [Related]  

  • 39. [Angiotensin converting enzyme inhibitors--a new group of hypotensive drugs].
    Lazowski J
    Wiad Lek; 1984 May; 37(10):792-6. PubMed ID: 6095537
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of angiotensin-converting enzyme: therapeutic implications.
    Rotmensch HH; Vlasses PH; Ferguson RK
    Isr J Med Sci; 1982 Oct; 18(10):981-5. PubMed ID: 6293997
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.